Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy

Inclusion Criteria:

Patients must have histologically I-III epithelial carcinoma of the ovary, fallopian tube or peritoneum or Stage IVA disease in which is there complete resolution of disease (pleural effusion) with chemotherapy
Patients must have undergone cytoreductive surgery and 3-8 cycles of platinum-based systemic chemotherapy prior to the second look surgery. Systemic platinum based chemotherapy must be completed less than 18 weeks prior to second look surgery.
Cytoreductive surgery must result in an R-0, R-1 resection prior to systemic chemotherapy
The intraoperative peritoneal adhesion index should be < 10.
Patients must be without clinical evidence of disease including a negative exam, imaging (CT or PET/CT) and normal tumor markers (CA125) after completion of systemic chemotherapy.
Age ≥ 18 years.
ECOG performance status ≤ 2.
Patients must have adequate organ and marrow function as defined below (within 30 days of registration): absolute neutrophil count >1,500/mcL; platelets >100,000/mcL; total bilirubin ≤ 1.5 mg/dL; creatinine clearance ≥ 50 mg/dL; AST(SGOT)/ALT(SGPT) ≤ 3X; institutional upper limit of normal; alkaline phosphatase 3X institutional upper limit of normal
Adequate contraception and negative pregnancy test if pregnancy possible.
Ability to understand and the willingness to sign an IRB-approved informed consent document.

Exclusion Criteria:

Patients greater than 18 weeks from their last course of systemic platinum based chemotherapy
Patients who have received additional chemotherapy for the ovarian cancer after primary therapy as outlined above.
Patients may not have received prior abdominal or pelvic radiation.
Extensive intra-abdominal adhesive disease noted at the time of initial cytoreductive surgery with PAI of >10 as defined above
Intra-abdominal infection associated with initial cytoreductive surgery requiring extended hospitalization or related to systemic chemotherapy requiring hospitalization for therapy
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin.
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Pregnancy

Men are excluded from participation due to the site-specific nature of the disease being studied.